Regeneron Pharmaceuticals

Tarrytown, United States· Est. 1988

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $40M

Market Cap: $80.5BPipeline: 200 drugs (96 Phase 3)Patents: 20Founded: 1988Employees: 10,000+HQ: Tarrytown, United States

Sector Ranking#40 in Biologics / Biosimilars #3 in Proteomics & Protein Engineering

Overview

Regeneron is a premier biotechnology company with a mission to translate groundbreaking science into life-changing medicines for patients. Its achievements are anchored by its proprietary VelociSuite® technology platforms, which have enabled the development of a robust commercial portfolio and one of the industry's deepest pipelines. The company's strategy combines sustained internal R&D investment with selective, high-value collaborations, all supported by a fully integrated model from discovery to global commercialization.

OphthalmologyCardiovascular & Metabolic DiseasesOncology & HematologyAllergic & Inflammatory DiseasesRare DiseasesInfectious DiseasesNeurosciencePain

Technology Platform

Proprietary VelociSuite® platform, including VelocImmune® (humanized mouse for fully human antibodies), VelociGene®, VelociMouse®, and Veloci-Bi® for bispecifics, integrated with the large-scale human genetics research of the Regeneron Genetics Center®.

Pipeline

200

200 drugs in pipeline96 in Phase 3

Drug	Indication	Stage
REGN5713 + REGN5714 + REGN5715 + Placebo	Allergic Rhinitis	Phase 3
Mibavademab	Monogenic Obesity	Phase 3
REGN10933 + REGN10987 + Placebo	Healthy Participants	Phase 3
garetosmab	Fibrodyplasia Ossificans Progressiva (FOP)	Phase 3
rilonacept 160 mg + Placebo + rilonacept 160 mg	Familial Cold Autoinflammatory Syndrome (FCAS)	Phase 3

Funding History

Total raised:$40M

IPO$40MUndisclosedApr 15, 1991

FDA Approved Drugs

LYNOZYFICBLAJul 2, 2025

EYLEA HDBLAAug 18, 2023

VEOPOZBLAAug 18, 2023

Opportunities

Significant growth opportunities exist from expanding Dupixent into new immunology indications (e.g., COPD), launching next-generation ophthalmology products, and successfully transitioning the pipeline into new commercial pillars in oncology and rare diseases.

The Regeneron Genetics Center provides a unique data advantage for target discovery and validation.

Risk Factors

Key risks include high reliance on EYLEA revenue facing impending patent expirations and competition, clinical trial failures in the expansive pipeline, and ongoing pricing pressures across global healthcare systems.

Competitive Landscape

Regeneron competes with large pharma and biotech peers across its core areas: vs. Roche/Genentech in ophthalmology, vs. Merck/BMS in oncology, and vs. Amgen/AstraZeneca in immunology. Its integrated platform and genetics capability provide key differentiators.